Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
SGEN's Cash to Debt is ranked higher than
98% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. SGEN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SGEN' s Cash to Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity to Asset 0.78
SGEN's Equity to Asset is ranked higher than
63% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. SGEN: 0.78 )
Ranked among companies with meaningful Equity to Asset only.
SGEN' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.61 Max: 0.96
Current: 0.78
0.36
0.96
Interest Coverage No Debt
SGEN's Interest Coverage is ranked higher than
98% of the 458 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SGEN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SGEN' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 4
Z-Score: 29.45
M-Score: -0.65
WACC vs ROIC
18.65%
-279.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -27.57
SGEN's Operating margin (%) is ranked higher than
62% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. SGEN: -27.57 )
Ranked among companies with meaningful Operating margin (%) only.
SGEN' s Operating margin (%) Range Over the Past 10 Years
Min: -401.85  Med: -107.91 Max: -23.35
Current: -27.57
-401.85
-23.35
Net-margin (%) -27.03
SGEN's Net-margin (%) is ranked higher than
61% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. SGEN: -27.03 )
Ranked among companies with meaningful Net-margin (%) only.
SGEN' s Net-margin (%) Range Over the Past 10 Years
Min: -359.97  Med: -109.43 Max: -23.22
Current: -27.03
-359.97
-23.22
ROE (%) -16.17
SGEN's ROE (%) is ranked higher than
64% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. SGEN: -16.17 )
Ranked among companies with meaningful ROE (%) only.
SGEN' s ROE (%) Range Over the Past 10 Years
Min: -128.57  Med: -40.02 Max: -16.17
Current: -16.17
-128.57
-16.17
ROA (%) -12.49
SGEN's ROA (%) is ranked higher than
65% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. SGEN: -12.49 )
Ranked among companies with meaningful ROA (%) only.
SGEN' s ROA (%) Range Over the Past 10 Years
Min: -50.86  Med: -23.41 Max: -12
Current: -12.49
-50.86
-12
ROC (Joel Greenblatt) (%) -190.19
SGEN's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. SGEN: -190.19 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SGEN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -903.49  Med: -523.09 Max: -178.02
Current: -190.19
-903.49
-178.02
Revenue Growth (3Y)(%) 13.40
SGEN's Revenue Growth (3Y)(%) is ranked higher than
64% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. SGEN: 13.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
SGEN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 7.7  Med: 40.5 Max: 148.1
Current: 13.4
7.7
148.1
EBITDA Growth (3Y)(%) 23.80
SGEN's EBITDA Growth (3Y)(%) is ranked higher than
77% of the 521 Companies
in the Global Biotechnology industry.

( Industry Median: 1.50 vs. SGEN: 23.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SGEN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -30.1  Med: 1 Max: 23.8
Current: 23.8
-30.1
23.8
EPS Growth (3Y)(%) 26.40
SGEN's EPS Growth (3Y)(%) is ranked higher than
81% of the 511 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. SGEN: 26.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SGEN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -34.2  Med: -3.2 Max: 27.7
Current: 26.4
-34.2
27.7
» SGEN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

SGEN Guru Trades in Q4 2015

Manning & Napier Advisors, Inc 357,750 sh (+41.70%)
PRIMECAP Management 12,882,175 sh (+0.13%)
Vanguard Health Care Fund Sold Out
Ray Dalio Sold Out
Jim Simons Sold Out
John Burbank Sold Out
Paul Tudor Jones Sold Out
Columbia Wanger 1,621,001 sh (-12.02%)
» More
Q1 2016

SGEN Guru Trades in Q1 2016

Columbia Wanger 1,763,796 sh (+8.81%)
PRIMECAP Management 13,589,187 sh (+5.49%)
Manning & Napier Advisors, Inc 289,140 sh (-19.18%)
» More
Q2 2016

SGEN Guru Trades in Q2 2016

Joel Greenblatt 30,082 sh (New)
George Soros 14,700 sh (New)
PRIMECAP Management 13,514,712 sh (-0.55%)
Columbia Wanger 1,428,393 sh (-19.02%)
Manning & Napier Advisors, Inc 228,321 sh (-21.03%)
» More
Q3 2016

SGEN Guru Trades in Q3 2016

Paul Tudor Jones 8,729 sh (New)
Manning & Napier Advisors, Inc 257,580 sh (+12.81%)
PRIMECAP Management 13,420,237 sh (-0.70%)
Columbia Wanger 682,974 sh (-52.19%)
George Soros 4,347 sh (-70.43%)
Joel Greenblatt 8,242 sh (-72.60%)
» More
» Details

Insider Trades

Latest Guru Trades with SGEN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:NVZMF, OTCPK:GMXAY, NAS:ALKS, OTCPK:UCBJY, NAS:TSRO, NAS:MDVN, OTCPK:GIKLY, NAS:JAZZ, NAS:UTHR, NAS:IONS, NAS:BMRN, NAS:EXEL, NAS:ALNY, NAS:TECH, NYSE:XON, NAS:RARE, NAS:ACAD, NAS:CBPO, NAS:ICPT, OTCPK:BTGGF » details
Traded in other countries:SGT.Germany,
Seattle Genetics Inc is a biotechnology company. It develops and commercializes monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease.

Seattle Genetics Inc was incorporated on July 15, 1997. It is a biotechnology company focused on the development and commercialization of targeted therapies for the treatment of cancer. Its marketed product ADCETRIS, or brentuximab vedotin, is approved by the United States Food and Drug Administration, or FDA, for three indications, encompassing several settings for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma, or sALCL. ADCETRIS is commercially available in more than 60 countries around the world, including in the United States, Canada, members of the European Union and Japan. It is collaborating with Takeda Pharmaceutical Company Limited, or Takeda, to develop and commercialize ADCETRIS on a global basis. Under this collaboration, Seattle Genetics retains commercial rights for ADCETRIS in the United States and its territories and in Canada, and Takeda has commercial rights in the rest of the world. In addition to ADCETRIS and SGN-CD33A, its clinical-stage pipeline includes five other antibody-drug conjugate, or ADC, programs consisting of SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and an immuno-oncology agent called SEA-CD40, which is based on our sugar-engineered antibody, or SEA, technology. It sells ADCETRIS through a limited number of pharmaceutical distributors.. Many third parties compete with the Company in developing various approaches to cancer and autoimmune disease therapy. It includes pharmaceutical companies, biotechnology companies, academic institutions and other research organizations. The Company operates under the regulations of FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries.

Ratios

vs
industry
vs
history
P/B 13.90
SGEN's P/B is ranked lower than
90% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. SGEN: 13.90 )
Ranked among companies with meaningful P/B only.
SGEN' s P/B Range Over the Past 10 Years
Min: 1.88  Med: 9.08 Max: 35.99
Current: 13.9
1.88
35.99
P/S 22.06
SGEN's P/S is ranked lower than
67% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. SGEN: 22.06 )
Ranked among companies with meaningful P/S only.
SGEN' s P/S Range Over the Past 10 Years
Min: 9.87  Med: 19.04 Max: 45.24
Current: 22.06
9.87
45.24
Current Ratio 5.92
SGEN's Current Ratio is ranked higher than
61% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. SGEN: 5.92 )
Ranked among companies with meaningful Current Ratio only.
SGEN' s Current Ratio Range Over the Past 10 Years
Min: 2.65  Med: 5.23 Max: 30.03
Current: 5.92
2.65
30.03
Quick Ratio 5.35
SGEN's Quick Ratio is ranked higher than
58% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. SGEN: 5.35 )
Ranked among companies with meaningful Quick Ratio only.
SGEN' s Quick Ratio Range Over the Past 10 Years
Min: 2.29  Med: 5.19 Max: 30.03
Current: 5.35
2.29
30.03
Days Inventory 541.18
SGEN's Days Inventory is ranked lower than
96% of the 448 Companies
in the Global Biotechnology industry.

( Industry Median: 128.70 vs. SGEN: 541.18 )
Ranked among companies with meaningful Days Inventory only.
SGEN' s Days Inventory Range Over the Past 10 Years
Min: 442.93  Med: 554.76 Max: 639.76
Current: 541.18
442.93
639.76
Days Sales Outstanding 58.49
SGEN's Days Sales Outstanding is ranked higher than
52% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. SGEN: 58.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
SGEN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 32.76  Med: 61.69 Max: 562.77
Current: 58.49
32.76
562.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.30
SGEN's 3-Year Average Share Buyback Ratio is ranked higher than
70% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. SGEN: -5.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SGEN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -113.5  Med: -12.7 Max: -2.2
Current: -5.3
-113.5
-2.2

Valuation & Return

vs
industry
vs
history
Price/Net Cash 22.76
SGEN's Price/Net Cash is ranked lower than
82% of the 518 Companies
in the Global Biotechnology industry.

( Industry Median: 6.05 vs. SGEN: 22.76 )
Ranked among companies with meaningful Price/Net Cash only.
SGEN' s Price/Net Cash Range Over the Past 10 Years
Min: 2.12  Med: 11.85 Max: 284.71
Current: 22.76
2.12
284.71
Price/Net Current Asset Value 16.56
SGEN's Price/Net Current Asset Value is ranked lower than
82% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 5.53 vs. SGEN: 16.56 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SGEN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.09  Med: 9.87 Max: 447
Current: 16.56
2.09
447
Price/Tangible Book 13.91
SGEN's Price/Tangible Book is ranked lower than
86% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. SGEN: 13.91 )
Ranked among companies with meaningful Price/Tangible Book only.
SGEN' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.78  Med: 6.54 Max: 33.75
Current: 13.91
1.78
33.75
Price/Median PS Value 1.16
SGEN's Price/Median PS Value is ranked lower than
65% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. SGEN: 1.16 )
Ranked among companies with meaningful Price/Median PS Value only.
SGEN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.53  Med: 1.13 Max: 30
Current: 1.16
0.53
30
Earnings Yield (Greenblatt) (%) -1.35
SGEN's Earnings Yield (Greenblatt) (%) is ranked higher than
69% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. SGEN: -1.35 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SGEN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -4.02  Med: 0 Max: 0
Current: -1.35
-4.02
0

More Statistics

Revenue (TTM) (Mil) $406.3
EPS (TTM) $ -0.78
Beta2.17
Short Percentage of Float20.07%
52-Week Range $26.02 - 75.36
Shares Outstanding (Mil)141.55

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 417 499 679 955
EPS ($) -1.04 -0.67 0.20 1.30
EPS w/o NRI ($) -1.04 -0.67 0.20 1.30
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for SGEN

Headlines

Articles On GuruFocus.com
Insiders Buy Herbalife, Sell MasterCard Nov 05 2016 
Insiders Roundup: Theravance Biopharma, Western Gas, Upland Software Mar 18 2016 
Top Insider Trades of the Past Week Feb 19 2016 
Insiders Are Buying Barnes & Noble Sep 18 2015 
Vanguard Health Care Fund Buys Two New Stakes in Second Quarter Aug 06 2015 
Insiders keep on buying Macerich Co and Seattle Genetics May 22 2015 
Insiders new buys : ZU, SGEN, MAC, SHLD, TBRA May 12 2015 
Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 

More From Other Websites
3:09 am Seattle Genetics and Bristol-Myers Squibb (BMY) highlight... Dec 06 2016
Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating... Dec 05 2016
Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell... Dec 05 2016
Seattle Genetics Highlights Phase 1 Vadastuximab Talirine (SGN-CD33A; 33A) Data Presentations,... Dec 05 2016
Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS®... Dec 03 2016
Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS®... Dec 03 2016
Takeda and Seattle Genetics Report Positive Phase 3 ALCANZA Clinical Trial Data of ADCETRIS®... Dec 03 2016
Seattle Genetics Presents Phase 1b Data from Vadastuximab Talirine (SGN-CD33A; 33A) in Combination... Dec 03 2016
Seattle Genetics Presents Data from Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in... Dec 03 2016
ETFs with exposure to Seattle Genetics, Inc. : December 2, 2016 Dec 02 2016
Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC Dec 01 2016
Hedge Funds Are Coming Back to Seattle Genetics, Inc. (SGEN) Dec 01 2016
[$$] Three Biotechs With Bullish Insider Buying Dec 01 2016
Seattle Genetics to Webcast Investor and Analyst Event at American Society of Hematology Annual... Nov 29 2016
[$$] Biotech M&A Could Surge Under Trump Nov 15 2016
Could Trump 'Make Drug Development Great Again'? Nov 14 2016
Incyte Corporation (INCY), Seattle Genetics, Inc. (SGEN) & Two More: Top Healthcare Hedge Fund Loves... Nov 14 2016
Massive Icahn Trades Highlight Huge Insider Buying: Hertz Global, Herbalife, CBRE, Seattle Genetics... Nov 13 2016
Seattle Genetics moves up FDA timeline for cash cow drug Adcetris Nov 11 2016
Could Trump Tax Cut Plans, Republican Congress Spur Biotech M&A? Nov 10 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)